US Broker Ratings

Insulet Corporation (PODD) Stock Analysis: Capitalizing on a 7.37% Potential Upside in the Healthcare Sector

Insulet Corporation (NASDAQ: PODD), a prominent player in the healthcare sector, has been making waves with its innovative insulin delivery systems. As a leader in the medical devices industry, Insulet’s..

UnitedHealth Group (UNH) Stock Analysis: Navigating a 27.70% Potential Upside in Healthcare Plans

Investors eyeing UnitedHealth Group Incorporated (NYSE: UNH) may find themselves intrigued by the promising 27.70% potential upside according to the latest analyst ratings. As a key player in the healthcare..

Hologic, Inc. (HOLX) Stock Analysis: Navigating Growth Potential in the Healthcare Sector

Hologic, Inc. (NASDAQ: HOLX), a prominent player in the healthcare sector specializing in medical instruments and supplies, offers investors an intriguing opportunity in the dynamic landscape of women’s health technologies...

Agilent Technologies, Inc. (A) Stock Analysis: Navigating a Potential 18% Upside with Robust Growth Metrics

Agilent Technologies, Inc. (NYSE: A), headquartered in Santa Clara, California, is a prominent player in the healthcare sector, particularly within the diagnostics and research industry. With a market capitalization of..

Amgen Inc. (AMGN) Investor Outlook: Strong Revenue Growth and a Promising 8.39% Potential Upside

Amgen Inc. (NASDAQ: AMGN), a titan in the healthcare sector, continues to capture the attention of investors with its robust financial health and strategic positioning in the drug manufacturing industry...

Mettler-Toledo International (MTD) Stock Analysis: Exploring a 5.12% Upside Potential in the Diagnostics & Research Sector

Mettler-Toledo International Inc. (NYSE: MTD), a prominent player in the healthcare sector under the diagnostics and research industry, offers a compelling investment opportunity with a potential upside of 5.12%, based..

Takeda Pharmaceutical (TAK) Stock Analysis: 14.47% Potential Upside Driven by Strong Dividend Yield

Takeda Pharmaceutical Company Limited (TAK), a stalwart in the healthcare sector, continues to capture investor interest with its robust portfolio and strategic partnerships. Headquartered in Tokyo, Japan, Takeda is a..

Natera, Inc. (NTRA) Stock Analysis: Decoding the Diagnostic Giant’s 16.94% Upside Potential

Natera, Inc. (NASDAQ: NTRA), a leading player in the healthcare sector specializing in diagnostics and research, has captured investor attention with its innovative portfolio and robust growth prospects. With a..

Johnson & Johnson (JNJ) Stock Analysis: Exploring a 9.13% Potential Upside and Robust Dividend Yield

Johnson & Johnson (NYSE: JNJ), a stalwart in the healthcare sector, continues to capture investor attention with its resilient business model and attractive financial attributes. With a market capitalization of..

Veeva Systems Inc. (VEEV) Stock Analysis: Navigating a $46 Billion Market Cap with Strong Revenue Growth

For individual investors eyeing the healthcare technology sector, Veeva Systems Inc. (NYSE: VEEV) offers a compelling opportunity. As a leading provider of cloud-based software solutions tailored for the life sciences..

Tenet Healthcare Corporation (THC) Stock Analysis: Navigating Growth with a Solid 7.53% Potential Upside

Tenet Healthcare Corporation (NYSE: THC), a major player in the U.S. healthcare sector, continues to capture investor interest with a market cap of $15.93 billion. With its headquarters in Dallas,..

IQVIA Holdings, Inc. (IQV) Stock Analysis: Exploring a 24.82% Upside Potential

IQVIA Holdings, Inc. (NYSE: IQV), a powerhouse in the healthcare sector, presents an intriguing opportunity for investors with its substantial market cap of $26.35 billion. Specializing in diagnostics and research,..

Thermo Fisher Scientific Inc (TMO) Stock Analysis: Is a 39% Upside Within Reach?

Thermo Fisher Scientific Inc (NYSE: TMO), a titan in the healthcare sector, is capturing investor attention with a potential upside of 39.39% according to analysts’ average target price. With a..

Gilead Sciences, Inc. (GILD) Stock Analysis: Navigating Healthcare Innovation with a 3.04% Upside Potential

Investors eyeing Gilead Sciences, Inc. (NASDAQ: GILD) may find the biopharmaceutical giant’s current market trajectory compelling. With a market capitalization of $139.89 billion, Gilead is a stalwart in the healthcare..

Medtronic plc (MDT) Stock Analysis: Evaluating the 9.14% Potential Upside for Investors

Medtronic plc (NYSE: MDT), a titan in the healthcare sector, remains a focal point for investors eyeing opportunities within the medical devices industry. Headquartered in Galway, Ireland, Medtronic’s expansive market..

Vertex Pharmaceuticals (VRTX) Stock Analysis: A Closer Look at the 11% Upside Potential

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leading player in the biotechnology sector, has been at the forefront of developing therapies for cystic fibrosis (CF), among other medical conditions. With a..

Novo Nordisk A/S (NVO) Stock Analysis: Exploring Its Robust Growth and 22.79% Upside Potential

Novo Nordisk A/S (NYSE: NVO), headquartered in Bagsvaerd, Denmark, is a prominent player in the healthcare sector, specifically within the drug manufacturing industry. With a staggering market cap of $334.5..

DexCom, Inc. (DXCM) Stock Analysis: Analyst Consensus Points to 13.59% Potential Upside

DexCom, Inc. (DXCM), a prominent player in the healthcare sector, particularly within the medical devices industry, continues to attract attention from individual investors and analysts alike. With a market capitalization..

AbbVie Inc. (ABBV) Stock Analysis: Evaluating a Promising 10% Potential Upside for Investors

AbbVie Inc. (NYSE: ABBV), a formidable player in the healthcare sector, continues to capture investor interest as it navigates the dynamic landscape of the pharmaceutical industry. With a market capitalization..

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Biotech Innovator with a 6.58% Upside Potential

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stands as a prominent player in the biotechnology sector, making significant strides in developing therapeutics based on ribonucleic acid interference (RNAi). With a market capitalization..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds